21 Ha’arba’a Street
Tel Aviv 6473921
Israel
972 3 541 3131
https://www.redhillbio.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 113
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Dror Ben-Asher | Co-Founder, CEO & Director | 734.59k | N/A | 1966 |
Mr. Gilead Raday MPhil, MSc | Chief Operating Officer | 445.38k | N/A | 1975 |
Mr. Adi Frish | Chief Corporate & Business Development Officer | 419.5k | N/A | 1970 |
Mr. Rick D. Scruggs | Chief Commercial Officer, President of RedHill Biopharma Inc. & Director | 607.05k | N/A | 1960 |
Mr. Razi Ingber | Chief Financial Officer | N/A | N/A | 1984 |
Ms. Alexandra Okmian | Senior Business Development & Investor Relations Manager | N/A | N/A | N/A |
Dr. Reza Fathi Ph.D. | Senior Vice President of Research & Development | 299.29k | N/A | 1955 |
Mr. Guy Goldberg | Chief Business Officer | 338.13k | N/A | 1976 |
Dr. June S. Almenoff FACP, M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1957 |
Ms. Patricia Anderson B.Sc. RAC | Senior Vice President of Regulatory Affairs | N/A | N/A | N/A |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
RedHill Biopharma Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.